Scientist using a microscope

Research leads the way

Elkedonia is developing a neuroplastogen with novel target and mechanism of action, able to induce neuroplasticity without the side effects of psychedelics or of classical antidepressants. Acting fast, without inducing sedation, dependence or psychotic side effects: this is our ambition, based on our research data.

We are focusing on an innovative target, within neurons, in key brain circuits. Rather than acting at the synapse, our approach targets intracellular events and neuroplasticity, acting precisely on a highly selective signaling pathway.

Evidence from patients and preclinical research supports the involvement of our target in the pathophysiology of depression, and inhibiting its activity is expected to provide rapid and long-lasting relief for all patients. Our objective is to target key brain circuits to rewire resilience.

The key numbers

0 million

people are now living with depression worldwide, including teenagers and children1

0 %

of the patients do not respond
 to current treatments2

0rd

Suicide is the third leading cause of death in 15-29 years old3

0st

The WHO has projected that Major Depressive Disorder (MDD) will rank as the leading cause of socio-economic and medical burden worldwide by 20304

We are leading a pioneering approach

in antidepressant therapy

Our approach is unique

Elkedonia is committed to introducing a pioneering, first-in-class antidepressant treatment with precision medicine.

Innovation is crucial in the field of neuropsychiatry. Having a unique mode of action suggests potential for groundbreaking advancements in treating depression and co-morbidities associated with it.

By targeting adults, children, adolescents, and patients with comorbidities who are often overlooked in existing treatment options, Elkedonia demonstrates inclusivity and a commitment to addressing the needs of every patient.

We aim to provide not just a drug but a new holistic approach for personalized treatment, ensuring that patients receive the right treatment for their specific condition.

By actively seeking input from psychiatrists and patient associations, Elkedonia ensures its approach is aligned with real medical needs and patient preferences.

Contact us for more details
Discover the team

Together we can make a difference

1. World Health Organization. Depression and other common mental disorders: global health estimates. Available at: https://iris.who.int/bitstream/handle/10665/254610/w?sequence=1. Accessed November 2024. Prevalence and variability of depressive symptoms in Europe: update using representative data from the second and third waves of the European Health Interview Survey (EHIS-2 and EHIS-3). Arias-de la Torre, Jorge et al. The Lancet Public Health, Volume 8, Issue 11, e889 – e898

2. The STAR*D study: Treating depression in the real world.

3. World Health Organization. Suicide fact sheet, 2024. Available at: https://www.who.int/news-room/fact-sheets/detail/suicide. Accessed November 2024.

4. Depression. Malhi, Gin S et al. The Lancet, Volume 392, Issue 10161, 2299 – 2312